Original Research
Published on 09 Sep 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
in Cancer Immunity and Immunotherapy
![Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States](https://www.frontiersin.org/files/myhome article library/1464092/1464092_Thumb_400.jpg)
- 128 views
Original Research
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Review
Published on 09 Sep 2024
in Cancer Immunity and Immunotherapy
Review
Published on 09 Sep 2024
in Alloimmunity and Transplantation
Original Research
Published on 09 Sep 2024
in Lipids in Cardiovascular Disease
Review
Published on 09 Sep 2024
in Microbial Immunology
Original Research
Published on 09 Sep 2024
in Higher Education
Original Research
Published on 09 Sep 2024
in Functional and Applied Plant Genomics
Original Research
Published on 09 Sep 2024
in Nutrition and Metabolism
Original Research
Published on 09 Sep 2024
in Plant Breeding
Review
Published on 09 Sep 2024
in Addictive Behaviors
Hypothesis and Theory
Published on 09 Sep 2024
Brief Research Report
Published on 09 Sep 2024
in Social Impact of Tourism
Original Research
Published on 09 Sep 2024
in Sports Politics, Policy and Law
Original Research
Published on 09 Sep 2024
in Biology of Archaea
Original Research
Published on 09 Sep 2024
in Infectious Agents and Disease
Mini Review
Published on 09 Sep 2024
in Bioenergy and Biofuels